| NCT06388200 | A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa | RECRUITING | PHASE3 | 2024-06-18 | 2026-12-31 | 2026-12-31 |
| NCT05802329 | Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME) | RECRUITING | PHASE1 | 2024-01-13 | 2026-07-31 | 2026-07-31 |
| NCT05956626 | A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease | RECRUITING | PHASE2, PHASE3 | 2023-08-25 | 2026-09-28 | 2026-09-28 |
| NCT06018558 | Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2023-02-23 | 2026-05-29 | 2026-02-17 |
| NCT05258669 | Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults | UNKNOWN | PHASE2, PHASE3 | 2022-02-20 | 2023-10-31 | 2023-09-01 |
| NCT05203939 | Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2022-01-24 | 2027-03 | 2027-03 |
| NCT03591874 | Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease | TERMINATED | PHASE3 | 2018-12-23 | 2020-04-30 | 2020-04-30 |
| NCT03785340 | Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED) | COMPLETED | PHASE3 | 2018-12-03 | 2019-02-25 | 2019-02-25 |
| NCT03418727 | Dry Eye Disease Study With Brimonidine | COMPLETED | PHASE2 | 2017-09-06 | 2018-03-29 | 2018-03-29 |